We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
-2.48%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$75.3M
AUM Growth
-$24.5M
Cap. Flow
-$13.6M
Cap. Flow %
-18.01%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$12.6M
2
IMDZ
Immune Design Corp.
IMDZ
+$963K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$2.13B
$40.8M 54.17%
1,096,024
-353,721
-24% -$12.6M
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
$15.7M 20.86%
38,228
– –
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$13.6M 18.09%
2,531
– –
IMDZ
4
DELISTED
Immune Design Corp.
IMDZ
$4.82M 6.4%
1,236,394
-176,886
-13% -$963K
EGRX
5
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$362K 0.48%
6,777
– –

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q4 2017 Portfolio in Review

As of Q4 2017, ProQuest Associates IV held 5 positions worth $75.3M, down 25% from $99.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $13.6M in Q4 2017, reducing 2 holdings. Its largest reduction was UroGen Pharma, cutting an estimated $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q4 2017 reduction was UroGen Pharma, cutting an estimated $12.6M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $75.3M portfolio in Q4 2017.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q4 2017.
  • ProQuest Associates IV's portfolio value fell 25% quarter-over-quarter to $75.3M.

Based on ProQuest Associates IV's 13F filing for Q4 2017, filed 14 Feb 2018.